Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia (eBook)

Covering the history of breast cancer, theory of radiofrequency ablation (RFA), resection of carcinoma, imaging before and after non-surgical ablation therapy and quality of life, this book focuses on extensive breast-conserving treatment for the preservation of a cosmetically acceptable breast. It investigates the feasibility of percutaneous, minimally invasive techniques to ablate breast tumors and several modalities such as cryosurgery, laser ablation, thermoablation and high-intensity focused ultrasound. Non-surgical Ablation Therapy for Early-stage Breast Cancer centers on RFA and provides insights into cryoablation and focused ultrasound surgery. 

RFA has been shown to be effective for treating tumors in many types of tissue, including liver, bone, brain, kidney, pancreas and prostate. As such this book is a valuable resource for breast and general surgeons, radiation oncologists and medical oncologists in all areas. The extensive discussions enable scholars to gain radiological expertise and a basic understanding of molecular biology, leading to better surgery without scalpels.

Professor and Chairman of Department of Hematology in Saitama Medical Center, Saitama Medical University.

---

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.